MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Alternate Title

Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) in Patients With Unresectable Stage IV (Locally or Distantly Metastatic) Pancreatic Adenocarcinoma

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IITreatmentCompleted18 and overNCINCI-05-C-0141
NCI-P6557, MDX-010-24, NCT00112580

Special Category: NCI Web site featured trial

Trial Description

Purpose:

Biological therapies, such as MDX-010, may stimulate the immune system in different ways and stop tumor cells from growing.

This phase II trial is studying how well MDX-010 works in treating patients with stage IV pancreatic cancer that cannot be removed by surgery.

Eligibility:

Eligibility criteria include the following:

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive a 1½ hour infusion of MDX-010 every 3 weeks for approximately 2 months. Treatment may repeat approximately every 3 months for up to two courses. Some patients may then receive up to 2 more courses of treatment .

Patients will be evaluated at 3 weeks, every 3 months for 1 year, every 6 months for 2 years, and once a year thereafter.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

NCI - Center for Cancer Research

Steven Rosenberg, MD, PhD, Principal investigator
Ph: 301-496-4164
Email: sar@nih.gov

Related Information

Featured trial article

Registry Information

Official TitlePhase II Trial of Single Agent Ipilimumab (MDX-010 anti CTLA-4) for Subjects with Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Trial Start Date2005-07-18
Trial Completion Date2009-08-07
Registered in ClinicalTrials.govNCT00112580
Date Submitted to PDQ2005-04-25
Information Last Verified2009-08-26